Oligomeric Molecules Targeting HBV Genes for Viral Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis B infection lack effective methods for preventing or treating the virus, particularly in chronic cases, and existing therapies do not cure the infection, leading to limited options for managing liver cancer progression.
Innovation Solution
Development of oligomeric molecules that inhibit the expression of the Hepatitis B virus genome through RNA interference, targeting specific genes and proteins to prevent replication, maturation, and transmission, using novel combinations of linker groups and nucleotides in lipid nanoparticle formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral antiviral agents such as tenofovir or entecavir are used to treat chronic hepatitis B infection, then viral replication is suppressed, but the infection is not cured and treatment options for liver cancer progression remain limited
Solution Approach 1:
The patent segments the HBV genome into multiple distinct targets (pre-core region, core region, surface region, polymerase region, and X region), designing separate oligomeric molecules for each target. This segmentation allows comprehensive coverage of all viral functions, addressing both replication suppression and potential cancer progression by targeting multiple critical regions simultaneously.
Solution Approach 2:
The patent creates a universal therapeutic approach using oligomeric molecules that can target multiple HBV genes (C, P, S, and X) with a single treatment platform. This multi-functional approach addresses both viral replication and liver cancer progression, providing versatility beyond conventional single-target antivirals.
2Productivity
If conventional antiviral treatments are administered, then HBV replication is inhibited, but HBsAg and HBeAg persistence remains a marker for chronic liver disease and liver cancer risk
Solution Approach 1:
The patent applies local quality by designing specific oligomeric molecules that target distinct regions of the HBV genome with specialized functions. For example, pre-core targeted molecules address HBeAg production, surface targeted molecules address HBsAg clearance, and polymerase targeted molecules address replication. This region-specific approach ensures comprehensive antigen clearance while maintaining replication inhibition.
3Duration of action of moving object
If liver cancer treatment options such as surgery, chemotherapy, or transplantation are used, then life is prolonged for a few years, but no cure is achieved and progression remains rapid
Solution Approach 1:
The patent employs preliminary action by using oligomeric molecules to suppress HBV replication and clear antigens before liver cancer develops or progresses. By addressing the underlying viral infection comprehensively through multiple targeted regions, the treatment prevents cancer progression rather than merely prolonging life after cancer has established, potentially achieving curative outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligomeric molecules effectively reduce HBV viral titers, serum concentrations of HBsAg and HBeAg, and HBV DNA, providing a potent therapeutic approach that can inhibit all identified HBV genes, including C, P, S, and X, offering a significant advancement in treating Hepatitis B infection.
Implementation Method 1
Development of oligomeric molecules that inhibit the expression of the Hepatitis B virus genome through RNA interference
Data Source
AI summary
This invention encompasses compounds and compositions useful in methods for medical therapy, in general, for inhibiting Hepatitis B virus in a subject. The compounds have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers comprising UNA monomers and nucleic acid monomers, and the compounds are targeted to a sequence of an HBV genome.